· Partnerships & M&A· 日本語で読む
WIRobotics Partners With Ottobock for North American Sales of WIM S Walking-Assist Robot
WIRobotics USA and Otto Bock HealthCare LP signed a distribution and sales agreement for WIM S in the United States and Canada. Sales will begin in the United States, with online sales and opportunities to try the product at select orthotics and prosthetics clinics. Expansion into Canada and cooperation on the medical-use WIM Medi remain under consideration, subject to conditions.
Key facts
- WIRobotics USA signed a distribution and sales agreement with Otto Bock HealthCare LP for WIM S in the United States and Canada.
- The agreement was signed Oct. 15, and sales under the partnership will begin in the United States.
- In the United States, WIM S will be sold through Ottobock’s direct-sales online platform and the WIRobotics USA online store, and initially will be available to try at select O&P clinics.
- The WIM series is in its third year of commercialization and has exceeded 4,000 cumulative sales.
- Expansion of WIM Medi into the medical and rehabilitation fields in the United States and Canada requires regulatory approval and a separate agreement.
What happened
WIRobotics announced Nov. 16, 2026, that its U.S. subsidiary, WIRobotics USA, signed a distribution and sales agreement with Otto Bock HealthCare LP for its WIM S walking-assist robot in the United States and Canada. The agreement was signed Oct. 15, and sales will begin in the United States. WIM S will be available through Ottobock’s direct-sales online platform and the WIRobotics USA online store, the company said.
Why it matters
Alongside online sales of WIM S, WIRobotics says it will offer opportunities to try the product at select U.S. O&P clinics. The company is bringing the WIM series’ more than 4,000 cumulative sales to the North American market. Cooperation on WIM Medi, intended for medical use, is contingent on regulatory approval and a separate agreement, requiring a process distinct from general sales.
Analysis
WIRobotics says cumulative sales of the WIM series have exceeded 4,000 units in its third year of commercialization. The agreement establishes a distribution and sales structure for bringing those sales to North America. However, the 4,000 figure covers the entire series, and the company has not provided a regional breakdown or sales figures for WIM S alone. The figure does not by itself indicate the scale or pace of demand in North America.
The sales approach combines online purchasing with opportunities to try the product in person at select U.S. O&P clinics. The latter gives customers a chance to test the product before buying, but the companies have not disclosed how many clinics will participate initially or what share of trials lead to purchases. Cooperation will also cover market development, product training and after-sales service, with WIRobotics USA responsible for local training and service operations. The partnership thus sets up an operating structure that includes product trials and post-sale support, in addition to sales channels.
The United States will be the first market, while expansion into Canada is under consideration based on customer feedback. The companies have not announced a start date for sales in Canada or a U.S. sales target. The extent to which the partnership with Ottobock, which has a North American distribution, clinical care and service network, will provide regional coverage and ongoing support will need to be assessed as locations are added.
The focus here differs from humanoid.guide’s report on the Booster T2 as a developer-focused humanoid. WIM S’s North American rollout is about establishing sales, product trial and service channels for a walking-assist device, rather than a development environment for humanoids. Because WIM Medi, intended for medical use, requires regulatory approval and a separate agreement, its expansion into medical and rehabilitation fields is not currently at the same stage as general sales of WIM S. Product specifications, pricing, sales targets, the number of clinics, the timing of expansion into Canada and the status of approvals required for WIM Medi remain to be clarified.
Details
Initially, WIM S will be available to try at select orthotics and prosthetics (O&P) clinics in the United States. The companies plan to cooperate on market development, brand building, product training and after-sales service, with WIRobotics USA supporting local training and service operations. They will consider adding trial locations in the United States and expanding sales under the partnership into Canada based on customer feedback.
WIRobotics says the WIM series is in its third year of commercialization and has exceeded 4,000 cumulative sales. The companies are also considering expanding cooperation to WIM Medi, which is under development for medical use. However, expansion into the medical and rehabilitation fields in the United States and Canada will require approval from the relevant regulatory authorities and a separate agreement, the company said.
Sources
Translated from the Japanese original: /news/wirobotics-hokou-shien-robotto-wim-s-no-hokubei-hanbai-de-ot-b601bb. The Japanese version is authoritative if they differ.